Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Vasogen-- VAS on TSE -- Ignore unavailable to you. Want to Upgrade?

To: brb who wrote (234)	11/23/1999 4:58:00 PM
From: Julian	Respond to of 377

Immunal Biotech Company Info: Company: Vasogen Inc Symbol: VAS.TO Date of Review: 9/13/99 Rating: Buy Daily Stats: Last Trade: on 3:59PM it was at $5.35 Change: -0.70 or: -11.57% Volume: 555,217 Average Volume: N/A Open: 6.20 Day's Range: 5.25 - 6.25 Our Portfolio: Value at Time of Review: $3.000 (+2.350/+0.439%) -------------------------------------------------------------------------------- A HEART SAVER ----A COMPOUND TO REDUCE ATHEROSCLEROSIS AND TO LOWER CHOLESTEROL ......... PLUS MUCH MORE! Vasogen Inc. is a medical research company whose notable developments are centered around the prevention of cardiovascular disease and treatment for the complications that arise during the invasive surgery procedures that are inherent in the corrective process. Their major accomplishment is the development of proprietary immune modulation therapies for use in the treatment of cardiovascular, autoimmune and related inflammatory diseases. In April of this year researchers announced results from pre-clinical studies that showed the use of Vasogen's therapy reduced the development of atherosclerosis by up to 75%. Atherosclerosis is the build up of cholesterol plaque within blood vessels, the major cause of cardiovascular disease, and this disease is the leading cause of death and disability in developed countries. Cardiovascular disease costs health care systems in excess of $300 billion annually and is the cause of more than 500,000 deaths each year in North America alone. The market for cholesterol lowering drug therapies aimed at cardiovascular disease is in excess of $5 billion annually just in the U.S. and is growing more than 20% per year. Two other major therapies under development at this time are: (i) a compound that will protect organs from being damaged during major vascular surgery and; (ii) a compound for the prevention of Graft-versus-Host disease in patients receiving bone marrow transplants. Each of these therapies is immense in scope. As with all medical research they must go through numerous pre-clinical studies and clinical trials. Recent speculation is that trials of the therapy for the protection of organs during major vascular surgery are about to get underway at Baylor College of Medicine, a premier heart center in Texas. A U.S. trial is a significant milestone. In January the company appointed Dr. Robert Roberts to their Scientific Advisory Board. Dr. Roberts is head of the cardiology department at Baylor College. On September 8, 1999 they announced the appointment of Terrance Gregg to the Board of Directors. Mr. Gregg is the president and COO of MiniMed Inc. where, in this capacity, since 1996 he has lead that company to a four fold increase in revenues and a fifteen fold increase in market cap. MiniMed Inc. is a world leader in diabetes management systems. Two very prestigious appointments. As a pure research and development company at this time Vasogen has no revenues and operates primarily at a loss and is dependent on institutional financing to maintain a positive cash flow. In 1999 the company is maintaining cash resources in the order of $11-$12 million. Share values have risen over 30% recently just on the speculation of U.S. trials of the one therapy. They touched $3.15, a 52 week high and have almost doubled for the year. A formal announcement from the U.S. Food and Drug Administration for the beginning of trials at Baylor College will likely cause another small surge in price. Vasogen is a newcomer to the TSE. It was listed for trading on July 22, 1999 after being listed for approximately four years on the Canadian Dealing Network and the ME. It is also currently listed on the over-the-counter bulletin board in the U.S. The listing has made a sparkling entrance to the exchange, reaching its 52 week high and being a near volume leader after only 7 weeks. What I Would Do Vasogen is a dynamic growth prospect that is at the leading edge of a gigantic breakthrough in the prevention of heart disease. The potential is enormous. I consider this to be a ‘VALUE BUY'. Reviewed By: bastard [ return to the top of this page ]

To: brb who wrote (234)	11/25/1999 10:51:00 AM
From: dean_k	Read Replies (1) \| Respond to of 377

We are clearly in a bull flag and received the ASE news at the recent peak. Need to see some recovery of volume on uptrend continuation. Influence of Turkey Day?? 207.161.229.210 Since the 17th the net house positions are Net buyers have been ... T 9 Nesbitt 246693 T 85 ScotiaMcLeod 126106 T 15 Bunting 107600 T 7 Green Line 54490 T 39 Midland 48414 T 33 Canaccord 37700 The net sellers T 63 Levesque Beaubien -77760 T 83 Research Capital -77935 T 80 First Marathon -129758 T 88 Versus -140700 T 45 Loewen -158400 humbly, Dean